Logo image of XFOR

X4 PHARMACEUTICALS INC (XFOR) Stock Fundamental Analysis

NASDAQ:XFOR - Nasdaq - US98420X1037 - Common Stock - Currency: USD

0.1872  -0.01 (-7%)

Premarket: 0.177 -0.01 (-5.45%)

Fundamental Rating

2

Overall XFOR gets a fundamental rating of 2 out of 10. We evaluated XFOR against 568 industry peers in the Biotechnology industry. Both the profitability and financial health of XFOR have multiple concerns. XFOR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

XFOR had negative earnings in the past year.
XFOR had a negative operating cash flow in the past year.
In the past 5 years XFOR always reported negative net income.
In the past 5 years XFOR always reported negative operating cash flow.
XFOR Yearly Net Income VS EBIT VS OCF VS FCFXFOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

The Return On Assets of XFOR (-25.57%) is better than 71.65% of its industry peers.
XFOR has a Return On Equity of -169.08%. This is in the lower half of the industry: XFOR underperforms 65.67% of its industry peers.
Industry RankSector Rank
ROA -25.57%
ROE -169.08%
ROIC N/A
ROA(3y)-52.08%
ROA(5y)-58.87%
ROE(3y)-165.72%
ROE(5y)-148.38%
ROIC(3y)N/A
ROIC(5y)N/A
XFOR Yearly ROA, ROE, ROICXFOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

With an excellent Gross Margin value of 68.83%, XFOR belongs to the best of the industry, outperforming 80.99% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for XFOR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XFOR Yearly Profit, Operating, Gross MarginsXFOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

2

2. Health

2.1 Basic Checks

XFOR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XFOR has more shares outstanding
The number of shares outstanding for XFOR has been increased compared to 5 years ago.
XFOR has a worse debt/assets ratio than last year.
XFOR Yearly Shares OutstandingXFOR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
XFOR Yearly Total Debt VS Total AssetsXFOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

XFOR has an Altman-Z score of -7.29. This is a bad value and indicates that XFOR is not financially healthy and even has some risk of bankruptcy.
XFOR's Altman-Z score of -7.29 is on the low side compared to the rest of the industry. XFOR is outperformed by 67.78% of its industry peers.
A Debt/Equity ratio of 3.41 is on the high side and indicates that XFOR has dependencies on debt financing.
XFOR has a Debt to Equity ratio of 3.41. This is amonst the worse of the industry: XFOR underperforms 82.57% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.41
Debt/FCF N/A
Altman-Z -7.29
ROIC/WACCN/A
WACC11.63%
XFOR Yearly LT Debt VS Equity VS FCFXFOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 3.41 indicates that XFOR has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.41, XFOR is doing worse than 60.21% of the companies in the same industry.
XFOR has a Quick Ratio of 3.33. This indicates that XFOR is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of XFOR (3.33) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.41
Quick Ratio 3.33
XFOR Yearly Current Assets VS Current LiabilitesXFOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

XFOR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -18.33%.
EPS 1Y (TTM)-18.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 18.97% on average over the next years. This is quite good.
Based on estimates for the next years, XFOR will show a very strong growth in Revenue. The Revenue will grow by 160.56% on average per year.
EPS Next Y24.72%
EPS Next 2Y21.08%
EPS Next 3Y22.9%
EPS Next 5Y18.97%
Revenue Next Year421.81%
Revenue Next 2Y254.09%
Revenue Next 3Y280.08%
Revenue Next 5Y160.56%

3.3 Evolution

XFOR Yearly Revenue VS EstimatesXFOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2020 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
XFOR Yearly EPS VS EstimatesXFOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

XFOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XFOR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XFOR Price Earnings VS Forward Price EarningsXFOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XFOR Per share dataXFOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as XFOR's earnings are expected to grow with 22.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.08%
EPS Next 3Y22.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XFOR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

X4 PHARMACEUTICALS INC

NASDAQ:XFOR (4/24/2025, 8:00:02 PM)

Premarket: 0.177 -0.01 (-5.45%)

0.1872

-0.01 (-7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25 2025-03-25/bmo
Earnings (Next)05-08 2025-05-08/bmo
Inst Owners58.44%
Inst Owner Change-0.07%
Ins Owners4.78%
Ins Owner Change62.82%
Market Cap32.51M
Analysts83.64
Price Target2.72 (1352.99%)
Short Float %5.36%
Short Ratio5.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.07%
Min EPS beat(2)-12.04%
Max EPS beat(2)-2.09%
EPS beat(4)0
Avg EPS beat(4)-343.13%
Min EPS beat(4)-1301.88%
Max EPS beat(4)-2.09%
EPS beat(8)3
Avg EPS beat(8)-164.2%
EPS beat(12)5
Avg EPS beat(12)-110.39%
EPS beat(16)6
Avg EPS beat(16)-87.73%
Revenue beat(2)1
Avg Revenue beat(2)-16.27%
Min Revenue beat(2)-67.57%
Max Revenue beat(2)35.03%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.86%
PT rev (3m)-12.52%
EPS NQ rev (1m)-30.59%
EPS NQ rev (3m)-0.91%
EPS NY rev (1m)-4.11%
EPS NY rev (3m)0.6%
Revenue NQ rev (1m)59.84%
Revenue NQ rev (3m)-20.92%
Revenue NY rev (1m)-8.37%
Revenue NY rev (3m)-30.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.71
P/FCF N/A
P/OCF N/A
P/B 1.47
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.71
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.75
OCFYN/A
SpS0.01
BVpS0.13
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.57%
ROE -169.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.83%
FCFM N/A
ROA(3y)-52.08%
ROA(5y)-58.87%
ROE(3y)-165.72%
ROE(5y)-148.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 3.41
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 920.35%
Cap/Sales 286.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.41
Quick Ratio 3.33
Altman-Z -7.29
F-Score3
WACC11.63%
ROIC/WACCN/A
Cap/Depr(3y)318.09%
Cap/Depr(5y)293.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y24.72%
EPS Next 2Y21.08%
EPS Next 3Y22.9%
EPS Next 5Y18.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year421.81%
Revenue Next 2Y254.09%
Revenue Next 3Y280.08%
Revenue Next 5Y160.56%
EBIT growth 1Y-31.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-43.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.63%
OCF growth 3YN/A
OCF growth 5YN/A